Similar articles

• Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.

  Ribas R, Pancholi S, Rani A, Schuster E, Guest SK, Nikitorowicz-Buniak J, Simigdala N, Thornhill A, Avogadri-Connors F, Cutler RE Jr, Lalani AS, Dowsett M, Johnston SR, Martin LA. Ribas R, et al. Breast Cancer Res. 2018 Jun 8;20(1):44. doi: 10.1186/s13058-018-0983-1. Breast Cancer Res. 2018. PMID: 29880014 Free PMC article.
• LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.

  Goel S, Sharma R, Hamilton A, Beith J. Goel S, et al. Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD004562. doi: 10.1002/14651858.CD004562.pub4. Cochrane Database Syst Rev. 2009. PMID: 19821328 Free PMC article.
• Upregulated SAE1 Drives Tumorigenesis and Is Associated with Poor Clinical Outcomes in Breast Cancer.

  Liu H, Wang J, Li Y, Luo F, Xing L. Liu H, et al. Breast J. 2024 Jun 30;2024:2981722. doi: 10.1155/2024/2981722. eCollection 2024. Breast J. 2024. PMID: 39742381 Free PMC article.
• Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.

  Gibson L, Lawrence D, Dawson C, Bliss J. Gibson L, et al. Cochrane Database Syst Rev. 2009 Oct 7;2009(4):CD003370. doi: 10.1002/14651858.CD003370.pub3. Cochrane Database Syst Rev. 2009. PMID: 19821307 Free PMC article.
• Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.

  Pancholi S, Leal MF, Ribas R, Simigdala N, Schuster E, Chateau-Joubert S, Zabaglo L, Hills M, Dodson A, Gao Q, Johnston SR, Dowsett M, Cosulich SC, Maragoni E, Martin LA. Pancholi S, et al. Breast Cancer Res. 2019 Dec 4;21(1):135. doi: 10.1186/s13058-019-1222-0. Breast Cancer Res. 2019. PMID: 31801615 Free PMC article.